NetraMark.AI

NetraMark offers explainable AI solutions to the Pharma Industry. Delivering insights to optimize trial design, improve success & explain efficacy in subgroups

[NetraMark.AI @NetraMark_AI]

Thank you @ASCPorg for another great #ASCP2026 meeting! Our team enjoyed participating in the plenary panel, 2 days of poster presentations, & networking with other thought leaders in #psychopharmacology. Request our plenary presentation or posters at https://t.co/QYefcaQL7O

[NetraMark.AI @NetraMark_AI]

Our team is getting ready for @ASCPorg's annual meeting next week in Miami! With two posters and a plenary session, we're looking forward to lots of conversations & networking. Chat with our team at https://t.co/QYefcaQL7O
#ASCP2026 #NetraMark

[NetraMark.AI @NetraMark_AI]

Members of NetraMark's team were in Toronto this morning to open the market at the Toronto Stock Exchange! #TSX #NetraMark #AIAI #MarketOpen #Toronto #trading #innovation #AIforclinicaltrials

[NetraMark.AI @NetraMark_AI]

NetraMark opened the market on Tuesday, May 5, 2026! Watch at https://t.co/9YhBODaNL8
#TSX #NetraMark #AIAI #MarketOpen #Toronto #trading #innovation #AIforclinicaltrials

[NetraMark.AI @NetraMark_AI]

#Psychedelics are known to produce mind-expanding experiences where everything feels connected. We asked what if part of that isn't just #brain #chemistry, but involves #quantumphysics? Read our @FrontPharmacol #publication https://t.co/nrvaCrqgGS or news https://t.co/dZVO7VHTHj

[NetraMark.AI @NetraMark_AI]

A new collaboration for NetraAI to analyze a landmark #precisiononcology trial! We aim to uncover clinically actionable #patient #subpopulations & #biomarker-driven #treatment insights to inform future strategies & #clinicaltrialdesign. More at www.netramark.como/press-releases/

[NetraMark.AI @NetraMark_AI]

Today, at the @adpdnet Conference, we showed how #NetraAI uncovered clinically meaningful #treatmentresponder subgroups in the landmark Asymptomatic Alzheimer’s Disease #A4trial, hinting #therapeuticsignals may have been obscured in conventional analyses: https://t.co/YhVOFl1HVp

[NetraMark.AI @NetraMark_AI]

We've signed a new contract with a global biopharmaceutical company to analyze #Phase2 Depression #trialdata,  expanding our portfolio of AI-driven projects in #depression & #CNS disorders. Learn more at https://t.co/UPqbQY6hZh
#clinicaltrials #AIanalysis #NetraAI #pharma

[NetraMark.AI @NetraMark_AI]

NetraMark is going to @adpdnet! See our team members in Copenhagen between sessions or during our poster presentation. #ADPD26 #Alzheimers #Parkinsons #ADPD

[NetraMark.AI @NetraMark_AI]

Today marks the first day of trading on the Toronto Stock Exchange with our ticker: AIAI. Visit https://t.co/Om2BdoMV21 for key details.

[NetraMark.AI @NetraMark_AI]

We are #uplisting to the @tsx_tsxv! This is a significant milestone as we continue to scale #NetraAI. Trading on the #TorontoStockExchange will commence at market open on February 18, 2026. Learn more at https://t.co/dZVO7VHTHj

[NetraMark.AI @NetraMark_AI]

Ontario Research Fund's #ResearchExcellence #Award (ORF-RE) recognizes innovative partnerships driving #research excellence and technological advancements in #Ontario. Learn more about our collaborative work at https://t.co/dZVO7VHTHj
#AI #clincaltrials #Depression #schizophrenia

[NetraMark.AI @NetraMark_AI]

We engaged in a #CPIM with the #FDA! We presented #NetraAI for use as an enrichment methodology in #clinicaltrialdesign!  We're pleased to have received positive feedback & align with our mission of equipping sponsors with tech to achieve more successful clinical trial outcomes.

[The MidDay Bell @theMiddayBell]

#ClinicalTrials fail too often and explainable AI may finally fix that.
This episode breaks down how NetraAI @NetraMark_AI uncovers hidden signals in patient data to help good drugs reach the market..
$AIAI.CN $AINMF: A real paradigm shift in precision medicine.
#Biotech

[Rebecca Kerswell @rebeccakerswell]

Just interviewed @NetraMark_AI $AIAI.CN / $AINMF one of the most interesting AI companies in the clinical-trial space.

We covered:
• Why 60–90% of trials fail
• How “personas” can save or rescue Phase 2/3 studies
• Their partnership with Worldwide Clinical Trials
• FDA meeting coming this December
• NIMH collaboration + peer-reviewed publication

This company is doing things most AI companies can’t — explainable, regulator-aligned, real-world AI.

Full interview 👇
🎥 https://t.co/uTERyRLvaa

Not investment advice. I do not own shares and I was not paid.

[NetraMark.AI @NetraMark_AI]

Excited for our new partnership with Pentara! Together, we'll launch a novel site intelligence tool to enhance #clinicaltrial #integrity through advanced #AI #anomalydetection, enhancing confidence in #efficacy outcomes & assessment of #site irregularities.https://t.co/dZVO7VIrwR

[NetraMark.AI @NetraMark_AI]

Thrilled to announce an agreement with AlgoTx to optimize the #design of future #ATX01 trials. This #partnership will leverage cutting-edge technologies to accelerate development timelines & drive #trialsuccesses to improve #CIPN #patientlives. Read more: https://t.co/dZVO7VIrwR

[Giles @ahighelevation]

In a new @ZacksSmallCap CEO Chat, @NetraMark_AI $AINMF CEO George Achilleos details how the company’s AI identifies previously unrecognized subpopulations—helping pharma sponsors reduce trial risk and improve outcomes. https://t.co/wkrTGhbswZ

[Ontario Brain Institute @OntarioBrain]

🧠 Upcoming CfA Webinar | Revolutionizing Depression Care with AI
📅 Friday, July 18, 2025
🕛 12:00 – 1:00 PM ET

Join us for an innovation-driven webinar hosted by our Centre for Analytics, featuring @NetraMark_AI, a Toronto-based startup redefining how we diagnose and treat major depression.

Led by Dr. Goseph Geraci, NetraMark team is using mathematically enhanced AI to uncover hidden subtypes of depression and predict how individuals respond to treatment. Their work is powered by Brain-CODE, OBI’s state-of-the-art neuroinformatics platform. 🔬

Register to join:
https://t.co/ylnmsiluUO

[PRISM MarketView @PrismMarketView]

Can AI help save billions in failed clinical trials?

Toronto-based @NetraMark_AI (OTCQB: $AINMF) thinks so—and they have the data to back it up.

Their proprietary platform, NetraAI, just outperformed ChatGPT, DeepSeek, and traditional machine learning in uncovering high-impact patient subgroups across trials for schizophrenia, depression, and pancreatic cancer.
https://t.co/MAJxfDM8LV